Products
Aldastotug Biosimilar Monoclonal Antibody (Siglec-15) for Research
Cat No.: GMP-Bios-INN-1070
Anti-SIGLEC15/CD33L3 therapeutic antibody (Pre-made Aldastotug biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Aldastotug (development code BSI 060T) is a monoclonal antibody targeting Siglec-15 (SIGLEC15). It is developed by Pyxis Oncology for oncology. It is in Phase I clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1070-1mg | 1mg | 3090 |
| GMP-Bios-INN-1070-10mg | 10mg | |
| GMP-Bios-INN-1070-100mg | 100mg | |
| GMP-Bios-INN-1070-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Aldastotug biosimilar, Whole mAb, Anti-SIGLEC15/CD33L3 Antibody: Anti-Siglec-15/SIGLEC15/Sialic acid-binding Ig-like lectin 15/CD33 antigen-like 3 therapeutic antibody |
| INN Name | Aldastotug |
| Target | SIGLEC15/CD33L3 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2024 |
| Year Recommended | 2024 |
| Companies | Pyxis Oncology |
| Conditions Approved | na |
| Conditions Active | Oncology |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | Transgenic Mouse |
